Skip to main content

Table 4 Patient characteristics in the group younger than 80 years

From: Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age

  Early use of TLV Delayed use of TLV P value
(n = 79) (n = 67)
Body mass index (kg/m2) 21.7 ± 3.9 21.9 ± 4.2 0.778
NYHA class (II/III/IV) 1/68/10 0/54/13 0.203
CS class (I/II/III) 26/46/7 23/36/8 0.760
Systolic BP (mm Hg) on admission 131.7 ± 28.0 128.6 ± 31.7 0.533
Diastolic BP (mm Hg) on admission 69.7 ± 22.2 75.7 ± 17.9 0.073
Heart rate (bpm) 89.0 ± 23.5 94.7 ± 28.8 0.195
AST (IU/L) 62.4 ± 24.5 73.6 ± 24.9 0.750
ALT (IU/L) 51.6 ± 21.8 62.0 ± 25.2 0.754
eGFR (ml/min/1.73 m2) 49.0 ± 26.5 43.3 ± 21.5 0.156
Hemoglobin (g/dL) 12.6 ± 2.2 12.0 ± 3.2 0.229
Brain natriuretic peptide (pg/mL) 1153.2 ± 118.0 1529.3 ± 284.8 0.199
Ejection fraction (%) 45.3 ± 17.6 43.2 ± 19.5 0.509
HFpEF (n, %) 31, 39.2 25, 37.3 0.813
Length of hospital stay 21.0 ± 13.0 33.0 ± 22.7 < 0.001
Time until commencement of TLV from hospitalization 2.5 ± 1.0 12.7 ± 13.3 < 0.001
Length of hospital stay after initiation of TLV 18.6 ± 13.1 20.3 ± 16.9 0.479
  1. NYHA: New York Heart Association, CS: clinical scenario, BP: blood pressure, AST: aspartate aminotransferase, ALT: alanine aminotransferase, eGFR: estimated glomerular filtration rate, HFpEF: heart failure preserved ejection fraction, TLV: tolvaptan. Continuous data are expressed as the mean ± standard deviation or error. P-values were determined using the unpaired t-test